

Gail V W Johnson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8839128/publications.pdf>

Version: 2024-02-01

222
papers

25,352
citations

10070
75
h-index

8212
153
g-index

227
all docs

227
docs citations

227
times ranked

36904
citing authors

#	ARTICLE	IF	CITATIONS
1	Commentary: BAG3 as a Mediator of Endosome Function and Tau Clearance. <i>Neuroscience</i> , 2023, 518, 4-9.	1.1	4
2	The role of BAG3 in health and disease: A "Magic BAG of Tricks". <i>Journal of Cellular Biochemistry</i> , 2022, 123, 4-21.	1.2	18
3	BAG3 Regulation of RAB35 Mediates the Endosomal Sorting Complexes Required for Transport/Endolysosome Pathway and Tau Clearance. <i>Biological Psychiatry</i> , 2022, 92, 10-24.	0.7	10
4	Tau Post-Translational Modifications: Potentiators of Selective Vulnerability in Sporadic Alzheimer's Disease. <i>Biology</i> , 2021, 10, 1047.	1.3	14
5	Transglutaminase 2 as a therapeutic target for neurological conditions. <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 721-731.	1.5	10
6	Deletion or Inhibition of Astrocytic Transglutaminase 2 Promotes Functional Recovery after Spinal Cord Injury. <i>Cells</i> , 2021, 10, 2942.	1.8	7
7	The role of transglutaminase 2 in mediating glial cell function and pathophysiology in the central nervous system. <i>Analytical Biochemistry</i> , 2020, 591, 113556.	1.1	12
8	Presenilin 1 Regulates Membrane Homeostatic Pathways that are Dysregulated in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 961-977.	1.2	15
9	The Crosstalk Between Pathological Tau Phosphorylation and Mitochondrial Dysfunction as a Key to Understanding and Treating Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2020, 57, 5103-5120.	1.9	26
10	Tauopathy-associated tau modifications selectively impact neurodegeneration and mitophagy in a novel <i>C. elegans</i> single-copy transgenic model. <i>Molecular Neurodegeneration</i> , 2020, 15, 65.	4.4	35
11	A T231E Mutant that Mimics Pathologic Phosphorylation of Tau in Alzheimer's disease Causes Activation of the Mitochondrial Unfolded Protein Response in touch neurons. <i>MicroPublication Biology</i> , 2020, 2020, .	0.1	1
12	Tissue Transglutaminase-Mediated AT1 Receptor Sensitization Underlies Pro-inflammatory Cytokine LIGHT-Induced Hypertension. <i>American Journal of Hypertension</i> , 2019, 32, 476-485.	1.0	14
13	BAG3 and SYNPO (synaptopodin) facilitate phospho-MAPT/Tau degradation via autophagy in neuronal processes. <i>Autophagy</i> , 2019, 15, 1199-1213.	4.3	67
14	A tau homeostasis signature is linked with the cellular and regional vulnerability of excitatory neurons to tau pathology. <i>Nature Neuroscience</i> , 2019, 22, 47-56.	7.1	154
15	It's all about tau. <i>Progress in Neurobiology</i> , 2019, 175, 54-76.	2.8	134
16	Tau Clearance Mechanisms. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1184, 57-68.	0.8	17
17	Transglutaminase 2: Friend or foe? The discordant role in neurons and astrocytes. <i>Journal of Neuroscience Research</i> , 2018, 96, 1150-1158.	1.3	22
18	Depletion of transglutaminase 2 in neurons alters expression of extracellular matrix and signal transduction genes and compromises cell viability. <i>Molecular and Cellular Neurosciences</i> , 2018, 86, 72-80.	1.0	13

#	ARTICLE	IF	CITATIONS
19	Nrf2 mediates the expression of BAG3 and autophagy cargo adaptor proteins and tau clearance in an age-dependent manner. <i>Neurobiology of Aging</i> , 2018, 63, 128-139.	1.5	49
20	Nuclear transglutaminase 2 directly regulates expression of cathepsin S in rat cortical neurons. <i>European Journal of Neuroscience</i> , 2018, 48, 3043-3051.	1.2	7
21	Depletion of astrocytic transglutaminase 2 improves injury outcomes. <i>Molecular and Cellular Neurosciences</i> , 2018, 92, 128-136.	1.0	13
22	Inhibition or ablation of transglutaminase 2 impairs astrocyte migration. <i>Biochemical and Biophysical Research Communications</i> , 2017, 482, 942-947.	1.0	12
23	Transglutaminase 2 modulation of NF- κ B signaling in astrocytes is independent of its ability to mediate astrocytic viability in ischemic injury. <i>Brain Research</i> , 2017, 1668, 1-11.	1.1	20
24	Subcellular localization patterns of transglutaminase 2 in astrocytes and neurons are differentially altered by hypoxia. <i>NeuroReport</i> , 2017, 28, 1208-1214.	0.6	11
25	Assessing the degradation of tau in primary neurons: The role of autophagy. <i>Methods in Cell Biology</i> , 2017, 141, 229-244.	0.5	17
26	Endostatin and transglutaminase 2 are involved in fibrosis of the aging kidney. <i>Kidney International</i> , 2016, 89, 1281-1292.	2.6	46
27	The complex role of transglutaminase 2 in glioblastoma proliferation. <i>Neuro-Oncology</i> , 2016, 19, now157.	0.6	13
28	Fisetin stimulates autophagic degradation of phosphorylated tau via the activation of TFEB and Nrf2 transcription factors. <i>Scientific Reports</i> , 2016, 6, 24933.	1.6	86
29	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222.	4.3	4,701
30	Epigallocatechin-3-gallate enhances clearance of phosphorylated tau in primary neurons. <i>Nutritional Neuroscience</i> , 2016, 19, 21-31.	1.5	65
31	Mechanisms of tau and A β -induced excitotoxicity. <i>Brain Research</i> , 2016, 1634, 119-131.	1.1	40
32	Transglutaminases and Neurological Diseases. , 2015, , 283-314.		0
33	Autophagy in Alzheimer's disease. <i>Reviews in the Neurosciences</i> , 2015, 26, 385-95.	1.4	167
34	Tau facilitates A β -induced loss of mitochondrial membrane potential independent of cytosolic calcium fluxes in mouse cortical neurons. <i>Neuroscience Letters</i> , 2015, 597, 32-37.	1.0	23
35	BAG3 facilitates the clearance of endogenous tau in primary neurons. <i>Neurobiology of Aging</i> , 2015, 36, 241-248.	1.5	79
36	Transglutaminase Regulation of Cell Function. <i>Physiological Reviews</i> , 2014, 94, 383-417.	13.1	353

#	ARTICLE	IF	CITATIONS
37	NDP52 associates with phosphorylated tau in brains of an Alzheimer disease mouse model. <i>Biochemical and Biophysical Research Communications</i> , 2014, 454, 196-201.	1.0	34
38	Phosphorylated tau potentiates A β -induced mitochondrial damage in mature neurons. <i>Neurobiology of Disease</i> , 2014, 71, 260-269.	2.1	55
39	Sulforaphane induces autophagy through ERK activation in neuronal cells. <i>FEBS Letters</i> , 2014, 588, 3081-3088.	1.3	55
40	Nrf2 reduces levels of phosphorylated tau protein by inducing autophagy adaptor protein NDP52. <i>Nature Communications</i> , 2014, 5, 3496.	5.8	265
41	P1-005: SELECTIVELY ENHANCING PATHOLOGICAL FORMS OF TAU VIA THE AUTOPHAGY PATHWAY. , 2014, 10, P306-P306.		0
42	Transglutaminase and Polyamination of Tubulin: Posttranslational Modification for Stabilizing Axonal Microtubules. <i>Neuron</i> , 2013, 78, 109-123.	3.8	167
43	Mitochondrial permeability transition pore induces mitochondria injury in Huntington disease. <i>Molecular Neurodegeneration</i> , 2013, 8, 45.	4.4	88
44	Transglutaminase 2 facilitates or ameliorates HIF signaling and ischemic cell death depending on its conformation and localization. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2013, 1833, 1-10.	1.9	35
45	Tau Clearance Mechanisms and Their Possible Role in the Pathogenesis of Alzheimer Disease. <i>Frontiers in Neurology</i> , 2013, 4, 122.	1.1	174
46	Impaired Mitochondrial Dynamics and Nrf2 Signaling Contribute to Compromised Responses to Oxidative Stress in Striatal Cells Expressing Full-Length Mutant Huntingtin. <i>PLoS ONE</i> , 2013, 8, e57932.	1.1	80
47	Vena cava and aortic smooth muscle cells express transglutaminases 1 and 4 in addition to transglutaminase 2. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2012, 302, H1355-H1366.	1.5	26
48	Truncated tau and A β cooperatively impair mitochondria in primary neurons. <i>Neurobiology of Aging</i> , 2012, 33, 619.e25-619.e35.	1.5	103
49	Guidelines for the use and interpretation of assays for monitoring autophagy. <i>Autophagy</i> , 2012, 8, 445-544.	4.3	3,122
50	Metabolic State Determines Sensitivity to Cellular Stress in Huntington Disease: Normalization by Activation of PPAR γ . <i>PLoS ONE</i> , 2012, 7, e30406.	1.1	34
51	Transglutaminase 2: A molecular Swiss army knife. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2012, 1823, 406-419.	1.9	202
52	Complete transglutaminase 2 ablation results in reduced stroke volumes and astrocytes that exhibit increased survival in response to ischemia. <i>Neurobiology of Disease</i> , 2012, 45, 1042-1050.	2.1	40
53	Decreases in valosin-containing protein result in increased levels of tau phosphorylated at Ser262/356. <i>FEBS Letters</i> , 2011, 585, 3424-3429.	1.3	8
54	Cytosolic Guanine Nucleotide Binding Deficient Form of Transglutaminase 2 (R580a) Potentiates Cell Death in Oxygen Glucose Deprivation. <i>PLoS ONE</i> , 2011, 6, e16665.	1.1	36

#	ARTICLE	IF	CITATIONS
55	The toxicity of tau in Alzheimer disease: turnover, targets and potential therapeutics. <i>Journal of Cellular and Molecular Medicine</i> , 2011, 15, 1621-1635.	1.6	65
56	The Application Of Permanent Middle Cerebral Artery Ligation in the Mouse. <i>Journal of Visualized Experiments</i> , 2011, , .	0.2	17
57	Transglutaminase 2 and Its Role in Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 184, 699-707.	2.5	151
58	The interrelationship between mitochondrial dysfunction and transcriptional dysregulation in Huntington disease. <i>Journal of Bioenergetics and Biomembranes</i> , 2010, 42, 199-205.	1.0	62
59	Transglutaminase 2 protects against ischemic stroke. <i>Neurobiology of Disease</i> , 2010, 39, 334-343.	2.1	42
60	AES/GRG5: More than just a dominantâ€negative TLE/GRG family member. <i>Developmental Dynamics</i> , 2010, 239, 2795-2805.	0.8	33
61	A Caspase Cleaved Form of Tau Is Preferentially Degraded through the Autophagy Pathway. <i>Journal of Biological Chemistry</i> , 2010, 285, 21978-21987.	1.6	126
62	Split GFP Complementation Assay for Quantitative Measurement of Tau Aggregation In Situ. <i>Methods in Molecular Biology</i> , 2010, 670, 109-123.	0.4	22
63	Differential Modulation of TCF/LEF-1 Activity by the Soluble LRP6-ICD. <i>PLoS ONE</i> , 2010, 5, e11821.	1.1	15
64	The role of tau kinases in Alzheimer's disease. <i>Current Opinion in Drug Discovery & Development</i> , 2010, 13, 595-603.	1.9	89
65	Increased expression of Bim contributes to the potentiation of serum deprivation-induced apoptotic cell death in Huntington's disease knock-in striatal cell line. <i>Neurological Research</i> , 2009, 31, 77-83.	0.6	20
66	Phosphorylation of PPP(S/T)P motif of the free LRP6 intracellular domain is not required to activate the Wnt/Î²â€catenin pathway and attenuate GSK3Î² activity. <i>Journal of Cellular Biochemistry</i> , 2009, 108, 886-895.	1.2	10
67	Role of mitochondrial dysfunction in the pathogenesis of Huntington's disease. <i>Brain Research Bulletin</i> , 2009, 80, 242-247.	1.4	135
68	Caspase-cleaved Tau Expression Induces Mitochondrial Dysfunction in Immortalized Cortical Neurons. <i>Journal of Biological Chemistry</i> , 2009, 284, 18754-18766.	1.6	146
69	Intracellular Localization and Conformational State of Transglutaminase 2: Implications for Cell Death. <i>PLoS ONE</i> , 2009, 4, e6123.	1.1	66
70	Tau Protein Is Hyperphosphorylated in a Site-Specific Manner in Apoptotic Neuronal PC12 Cells. <i>Journal of Neurochemistry</i> , 2008, 75, 2346-2357.	2.1	43
71	p38 Kinase Is Activated in the Alzheimer's Disease Brain. <i>Journal of Neurochemistry</i> , 2008, 72, 2053-2058.	2.1	341
72	New application of Î²â€galactosidase complementation to monitor tau selfâ€association. <i>Journal of Neurochemistry</i> , 2008, 106, 1545-1551.	2.1	7

#	ARTICLE	IF	CITATIONS
73	Histone deacetylase 6 interacts with the microtubule-associated protein tau. <i>Journal of Neurochemistry</i> , 2008, 106, 2119-2130.	2.1	312
74	Immortalized cortical neurons expressing caspase-cleaved tau are sensitized to endoplasmic reticulum stress induced cell death. <i>Brain Research</i> , 2008, 1234, 206-212.	1.1	36
75	Transglutaminase 2 protects against ischemic insult, interacts with HIF1 ² , and attenuates HIF1 signaling. <i>FASEB Journal</i> , 2008, 22, 2662-2675.	0.2	71
76	Rosiglitazone Treatment Prevents Mitochondrial Dysfunction in Mutant Huntingtin-expressing Cells. <i>Journal of Biological Chemistry</i> , 2008, 283, 25628-25637.	1.6	117
77	The Last Tangle of Tau. <i>Journal of Alzheimer's Disease</i> , 2008, 14, 441-447.	1.2	25
78	Activation of Glycogen Synthase Kinase 3 ² Promotes the Intermolecular Association of Tau. <i>Journal of Biological Chemistry</i> , 2007, 282, 23410-23417.	1.6	39
79	Mitochondrial-targeted active Akt protects SH-SY5Y neuroblastoma cells from staurosporine-induced apoptotic cell death. <i>Journal of Cellular Biochemistry</i> , 2007, 102, 196-210.	1.2	38
80	Ubiquitin-proteasome system alterations in a striatal cell model of huntington's disease. <i>Journal of Neuroscience Research</i> , 2007, 85, 1774-1788.	1.3	43
81	Regulated proteolytic processing of LRP6 results in release of its intracellular domain. <i>Journal of Neurochemistry</i> , 2007, 101, 517-529.	2.1	37
82	Type 2 transglutaminase differentially modulates striatal cell death in the presence of wild type or mutant huntingtin. <i>Journal of Neurochemistry</i> , 2007, 102, 25-36.	2.1	22
83	Split GFP complementation assay: a novel approach to quantitatively measure aggregation of tau <i>in situ</i> : effects of GSK3 ² activation and caspase 3 cleavage. <i>Journal of Neurochemistry</i> , 2007, 103, 2529-2539.	2.1	69
84	The role of tau phosphorylation and cleavage in neuronal cell death. <i>Frontiers in Bioscience - Landmark</i> , 2007, 12, 733.	3.0	113
85	Transglutaminase 2 in neurodegenerative disorders. <i>Frontiers in Bioscience - Landmark</i> , 2007, 12, 891.	3.0	63
86	Tau Is Hyperphosphorylated at Multiple Sites in Mouse Brain In Vivo After Streptozotocin-Induced Insulin Deficiency. <i>Diabetes</i> , 2006, 55, 3320-3325.	0.3	169
87	The protective effects of cystamine in the R6/2 Huntington's disease mouse involve mechanisms other than the inhibition of tissue transglutaminase. <i>Neurobiology of Aging</i> , 2006, 27, 871-879.	1.5	70
88	Tau phosphorylation and proteolysis: Insights and perspectives. <i>Journal of Alzheimer's Disease</i> , 2006, 9, 243-250.	1.2	61
89	Tissue transglutaminase overexpression in the brain potentiates calcium-induced hippocampal damage. <i>Journal of Neurochemistry</i> , 2006, 97, 582-594.	2.1	45
90	The Role of Tau Phosphorylation in the Pathogenesis of Alzheimers Disease. <i>Current Alzheimer Research</i> , 2006, 3, 449-463.	0.7	124

#	ARTICLE	IF	CITATIONS
91	Mutant Huntingtin Expression Induces Mitochondrial Calcium Handling Defects in Clonal Striatal Cells. <i>Journal of Biological Chemistry</i> , 2006, 281, 34785-34795.	1.6	116
92	The Low Density Lipoprotein Receptor-related Protein 6 Interacts with Glycogen Synthase Kinase 3 and Attenuates Activity. <i>Journal of Biological Chemistry</i> , 2006, 281, 4787-4794.	1.6	80
93	Site-specific Phosphorylation and Caspase Cleavage Differentially Impact Tau-Microtubule Interactions and Tau Aggregation. <i>Journal of Biological Chemistry</i> , 2006, 281, 19107-19114.	1.6	100
94	Verification of somatic CAG repeat expansion by pre-PCR fractionation. <i>Journal of Neuroscience Methods</i> , 2005, 144, 11-17.	1.3	11
95	Transglutaminases in Neurodegenerative Disorders. , 2005, 38, 139-157.		18
96	Tissue transglutaminase contributes to disease progression in the R6/2 Huntington's disease mouse model via aggregate-independent mechanisms. <i>Journal of Neurochemistry</i> , 2005, 92, 83-92.	2.1	79
97	Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease. <i>Journal of Neurochemistry</i> , 2005, 95, 210-220.	2.1	96
98	Role of the intracellular domains of LRP5 and LRP6 in activating the Wnt canonical pathway. <i>Journal of Cellular Biochemistry</i> , 2005, 95, 328-338.	1.2	57
99	FRAT-2 Preferentially Increases Glycogen Synthase Kinase 3 ^β -mediated Phosphorylation of Primed Sites, Which Results in Enhanced Tau Phosphorylation. <i>Journal of Biological Chemistry</i> , 2005, 280, 270-276.	1.6	18
100	Mitochondrial Respiration and ATP Production Are Significantly Impaired in Striatal Cells Expressing Mutant Huntingtin. <i>Journal of Biological Chemistry</i> , 2005, 280, 30773-30782.	1.6	221
101	14-3-3 ^σ does not increase GSK3 ^β -mediated tau phosphorylation in cell culture models. <i>Neuroscience Letters</i> , 2005, 384, 211-216.	1.0	14
102	Increased glutathione levels in cortical and striatal mitochondria of the R6/2 Huntington's disease mouse model. <i>Neuroscience Letters</i> , 2005, 386, 63-68.	1.0	37
103	Tau phosphorylation: physiological and pathological consequences. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2005, 1739, 280-297.	1.8	379
104	Primed phosphorylation of tau at Thr231 by glycogen synthase kinase 3 ^β (GSK3 ^β) plays a critical role in regulating tau's ability to bind and stabilize microtubules. <i>Journal of Neurochemistry</i> , 2004, 88, 349-358.	2.1	215
105	Glycogen Synthase Kinase 3 ^β Induces Caspase-cleaved Tau Aggregation in Situ. <i>Journal of Biological Chemistry</i> , 2004, 279, 54716-54723.	1.6	104
106	Striatal cells from mutant huntingtin knock-in mice are selectively vulnerable to mitochondrial complex II inhibitor-induced cell death through a non-apoptotic pathway. <i>Human Molecular Genetics</i> , 2004, 13, 669-681.	1.4	78
107	Intracellular Localization and Activity State of Tissue Transglutaminase Differentially Impacts Cell Death. <i>Journal of Biological Chemistry</i> , 2004, 279, 8715-8722.	1.6	103
108	Mutant (R406W) Human Tau Is Hyperphosphorylated and Does Not Efficiently Bind Microtubules in a Neuronal Cortical Cell Model. <i>Journal of Biological Chemistry</i> , 2004, 279, 7893-7900.	1.6	45

#	ARTICLE	IF	CITATIONS
109	Cyclin-dependent kinase-5 in neurodegeneration. <i>Journal of Neurochemistry</i> , 2004, 88, 1313-1326.	2.1	132
110	Cyclin-dependent kinase-5 in neurodegeneration. <i>Journal of Neurochemistry</i> , 2004, 89, 528-528.	2.1	1
111	Developmental regulation of tissue transglutaminase in the mouse forebrain. <i>Journal of Neurochemistry</i> , 2004, 91, 1369-1379.	2.1	36
112	Tissue transglutaminase triggers oligomerization and activation of dual leucine zipper-bearing kinase in calphostin C-treated cells to facilitate apoptosis. <i>Cell Death and Differentiation</i> , 2004, 11, 542-549.	5.0	34
113	The glamour and gloom of glycogen synthase kinase-3. <i>Trends in Biochemical Sciences</i> , 2004, 29, 95-102.	3.7	1,400
114	Tissue transglutaminase is not involved in the aggregate formation of stably expressed τ -synuclein in sh-sy5y human neuroblastoma cells. <i>Archives of Pharmacal Research</i> , 2004, 27, 850-856.	2.7	5
115	Immunoblot analysis reveals that isopeptide antibodies do not specifically recognize the τ -(13 -glutamyl)lysine bonds formed by transglutaminase activity. <i>Journal of Neuroscience Methods</i> , 2004, 134, 151-158.	1.3	26
116	Effects of cyclin-dependent kinase-5 activity on apoptosis and tau phosphorylation in immortalized mouse brain cortical cells. <i>Journal of Neuroscience Research</i> , 2004, 76, 110-120.	1.3	27
117	Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. <i>Human Molecular Genetics</i> , 2004, 13, 1407-1420.	1.4	438
118	Validity of mouse models for the study of tissue transglutaminase in neurodegenerative diseases. <i>Molecular and Cellular Neurosciences</i> , 2004, 25, 493-503.	1.0	28
119	Tau phosphorylation in neuronal cell function and dysfunction. <i>Journal of Cell Science</i> , 2004, 117, 5721-5729.	1.2	506
120	Cystamine Inhibits Caspase Activity. <i>Journal of Biological Chemistry</i> , 2003, 278, 3825-3830.	1.6	155
121	The p38 MAP kinase signaling pathway in Alzheimer's disease. <i>Experimental Neurology</i> , 2003, 183, 263-268.	2.0	88
122	Glycogen Synthase Kinase β Phosphorylates Tau at Both Primed and Unprimed Sites. <i>Journal of Biological Chemistry</i> , 2003, 278, 187-193.	1.6	220
123	Tissue Transglutaminase Directly Regulates Adenylyl Cyclase Resulting in Enhanced cAMP-response Element-binding Protein (CREB) Activation. <i>Journal of Biological Chemistry</i> , 2003, 278, 26838-26843.	1.6	38
124	Direct, activating interaction between glycogen synthase kinase-3 and p53 after DNA damage. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 7951-7955.	3.3	247
125	Transient osmotic stress facilitates mutant huntingtin aggregation. <i>NeuroReport</i> , 2002, 13, 2543-2546.	0.6	7
126	Mutant huntingtin aggregates do not sensitize cells to apoptotic stressors. <i>FEBS Letters</i> , 2002, 515, 61-65.	1.3	8

#	ARTICLE	IF	CITATIONS
127	Does tissue transglutaminase play a role in Huntington's disease?. <i>Neurochemistry International</i> , 2002, 40, 37-52.	1.9	32
128	Tau, where are we now?. <i>Journal of Alzheimer's Disease</i> , 2002, 4, 375-398.	1.2	83
129	Microtubule/MAP-Affinity Regulating Kinase (MARK) Is Activated by Phenylarsine Oxide In Situ and Phosphorylates Tau Within Its Microtubule-Binding Domain. <i>Journal of Neurochemistry</i> , 2002, 74, 1463-1468.	2.1	23
130	Impaired Mitochondrial Function Results in Increased Tissue Transglutaminase Activity In Situ. <i>Journal of Neurochemistry</i> , 2002, 75, 1951-1961.	2.1	39
131	Cdk5 phosphorylates p53 and regulates its activity. <i>Journal of Neurochemistry</i> , 2002, 81, 307-313.	2.1	92
132	Tissue transglutaminase differentially modulates apoptosis in a stimuli-dependent manner. <i>Journal of Neurochemistry</i> , 2002, 81, 780-791.	2.1	74
133	Axin negatively affects tau phosphorylation by glycogen synthase kinase 3 β . <i>Journal of Neurochemistry</i> , 2002, 83, 904-913.	2.1	22
134	Select Alterations in Protein Kinases and Phosphatases During Apoptosis of Differentiated PC12 Cells. <i>Journal of Neurochemistry</i> , 2002, 68, 2338-2347.	2.1	35
135	Identification of the N-terminal functional domains of Cdk5 by molecular truncation and computer modeling. <i>Proteins: Structure, Function and Bioinformatics</i> , 2002, 48, 447-453.	1.5	66
136	Glycogen Synthase Kinase 3 β Is Tyrosine Phosphorylated by PYK2. <i>Biochemical and Biophysical Research Communications</i> , 2001, 284, 485-489.	1.0	106
137	Tissue Transglutaminase Selectively Modifies Proteins Associated with Truncated Mutant Huntingtin in Intact Cells. <i>Neurobiology of Disease</i> , 2001, 8, 391-404.	2.1	31
138	Tissue transglutaminase is essential for neurite outgrowth in human neuroblastoma SH-SY5Y cells. <i>Neuroscience</i> , 2001, 102, 481-491.	1.1	112
139	Three different human tau isoforms and rat neurofilament light, middle and heavy chain proteins are cellular substrates for transglutaminase. <i>Neuroscience Letters</i> , 2001, 298, 9-12.	1.0	37
140	Complement activation by neurofibrillary tangles in Alzheimer's disease. <i>Neuroscience Letters</i> , 2001, 305, 165-168.	1.0	153
141	Hyperosmotic stress-induced apoptosis and tau phosphorylation in human neuroblastoma cells. <i>Journal of Neuroscience Research</i> , 2001, 65, 573-582.	1.3	39
142	Tau and HMW tau phosphorylation and compartmentalization in apoptotic neuronal PC12 cells. <i>Journal of Neuroscience Research</i> , 2001, 66, 203-213.	1.3	28
143	Cholinergic- and stress-induced signaling activities in cells overexpressing wild-type and mutant presenilin-1. <i>Brain Research</i> , 2001, 903, 226-230.	1.1	11
144	Tau phosphorylation during apoptosis of human SH-SY5Y neuroblastoma cells. <i>Brain Research</i> , 2001, 921, 31-43.	1.1	34

#	ARTICLE	IF	CITATIONS
145	Tissue Transglutaminase Does Not Contribute to the Formation of Mutant Huntingtin Aggregates. <i>Journal of Cell Biology</i> , 2001, 153, 25-34.	2.3	128
146	Modulation of tau phosphorylation and intracellular localization by cellular stress. <i>Biochemical Journal</i> , 2000, 345, 263.	1.7	16
147	Modulation of tau phosphorylation and intracellular localization by cellular stress. <i>Biochemical Journal</i> , 2000, 345, 263-270.	1.7	51
148	Transient oxidative stress in SH-SY5Y human neuroblastoma cells results in caspase dependent and independent cell death and tau proteolysis. <i>Journal of Neuroscience Research</i> , 2000, 61, 515-523.	1.3	34
149	Insulin-like growth factor-1 and insulin mediate transient site-selective increases in tau phosphorylation in primary cortical neurons. <i>Neuroscience</i> , 2000, 99, 305-316.	1.1	119
150	Tissue transglutaminase: a possible role in neurodegenerative diseases. <i>Progress in Neurobiology</i> , 2000, 61, 439-463.	2.8	159
151	Measurement of Calpain Activity In Vitro and In Situ Using a Fluorescent Compound and Tau as Substrates. , 2000, 144, 143-150.		9
152	Tau Protein in Normal and Alzheimer's Disease Brain*. <i>Journal of Alzheimer's Disease</i> , 1999, 1, 307-328.	1.2	50
153	Transient Increases in Intracellular Calcium Result in Prolonged Site-selective Increases in Tau Phosphorylation through a Glycogen Synthase Kinase 3 β -dependent Pathway. <i>Journal of Biological Chemistry</i> , 1999, 274, 21395-21401.	1.6	124
154	The Microtubule Binding of Tau and High Molecular Weight Tau in Apoptotic PC12 Cells Is Impaired because of Altered Phosphorylation. <i>Journal of Biological Chemistry</i> , 1999, 274, 35686-35692.	1.6	39
155	Rapid, single-step procedure for the identification of transglutaminase-mediated isopeptide crosslinks in amino acid digests. <i>Biomedical Applications</i> , 1999, 732, 65-72.	1.7	14
156	Insulin Transiently Increases Tau Phosphorylation. <i>Journal of Neurochemistry</i> , 1999, 72, 576-584.	2.1	222
157	Glycogen synthase kinase-3 β , β -catenin, and tau in postmortem bipolar brain. <i>Journal of Neural Transmission</i> , 1999, 106, 1217-1222.	1.4	62
158	Hippocampal microtubule-associated protein-2 alterations with contextual memory1Published on the World Wide Web on 28 January 1999.1. <i>Brain Research</i> , 1999, 821, 241-249.	1.1	70
159	Energy metabolism and protein phosphorylation during apoptosis: a phosphorylation study of tau and high-molecular-weight tau in differentiated PC12 cells*. <i>Biochemical Journal</i> , 1999, 340, 51.	1.7	9
160	Novel bimodal effects of the G-protein tissue transglutaminase on adrenoreceptor signalling. <i>Biochemical Journal</i> , 1999, 343, 541-549.	1.7	20
161	Novel bimodal effects of the G-protein tissue transglutaminase on adrenoreceptor signalling. <i>Biochemical Journal</i> , 1999, 343, 541.	1.7	5
162	Energy metabolism and protein phosphorylation during apoptosis: a phosphorylation study of tau and high-molecular-weight tau in differentiated PC12 cells*. <i>Biochemical Journal</i> , 1999, 340, 51-58.	1.7	25

#	ARTICLE	IF	CITATIONS
163	Tau Protein in Normal and Alzheimer's Disease Brain: An Update*. Journal of Alzheimer's Disease, 1999, 1, 329-351.	1.2	103
164	The interrelationship between selective tau phosphorylation and microtubule association. Brain Research, 1998, 798, 173-183.	1.1	60
165	Calcineurin inhibition prevents calpain-mediated proteolysis of tau in differentiated PC12 cells. Journal of Neuroscience Research, 1998, 53, 153-164.	1.3	42
166	Enhancement of Peroxynitrite-Induced Apoptosis in PC12 Cells by Fibroblast Growth Factor-1 and Nerve Growth Factor Requires p21Ras Activation and Is Suppressed by Bcl-2. Archives of Biochemistry and Biophysics, 1998, 356, 41-45.	1.4	33
167	Oxidative Stress Inhibits Calpain Activity in Situ. Journal of Biological Chemistry, 1998, 273, 13331-13338.	1.6	87
168	Distinct Nuclear Localization and Activity of Tissue Transglutaminase. Journal of Biological Chemistry, 1998, 273, 11991-11994.	1.6	149
169	Modulation of the in Situ Activity of Tissue Transglutaminase by Calcium and GTP. Journal of Biological Chemistry, 1998, 273, 2288-2295.	1.6	186
170	Tau complexes with phospholipase C- β 3 in situ. NeuroReport, 1998, 9, 67-71.	0.6	74
171	Tissue Transglutaminase Is an In Situ Substrate of Calpain: Regulation of Activity. Journal of Neurochemistry, 1998, 71, 240-247.	2.1	34
172	'Oxidation Inhibits Substrate Proteolysis by Calpain I but Not Autolysis. Journal of Biological Chemistry, 1997, 272, 2005-2012.	1.6	104
173	Transglutaminase activity is increased in Alzheimer's disease brain. Brain Research, 1997, 751, 323-329.	1.1	179
174	Phosphorylation of microtubule-associated protein tau on Ser 262 by an embryonic 100 kDa protein kinase. Brain Research, 1997, 767, 305-313.	1.1	18
175	Calpains: Intact and active?. BioEssays, 1997, 19, 1011-1018.	1.2	95
176	Involvement of the low-affinity neurotrophin receptor (p75NTR) in apoptosis of differentiated PC12 cells. Neuroscience Research Communications, 1997, 20, 137-146.	0.2	1
177	The β , Protein in Human Cerebrospinal Fluid in Alzheimer's Disease Consists of Proteolytically Derived Fragments. Journal of Neurochemistry, 1997, 68, 430-433.	2.1	154
178	Nerve Growth Factor Protects PC12 Cells Against Peroxynitrite-Induced Apoptosis via a Mechanism Dependent on Phosphatidylinositol 3-Kinase. Journal of Neurochemistry, 1997, 69, 53-59.	2.1	70
179	Ceramide Selectively Decreases Tau Levels in Differentiated PC12 Cells Through Modulation of Calpain I. Journal of Neurochemistry, 1997, 69, 1020-1030.	2.1	37
180	Differential Binding of Apolipoprotein E Isoforms to Tau and Other Cytoskeletal Proteins. Experimental Neurology, 1996, 138, 252-260.	2.0	80

#	ARTICLE	IF	CITATIONS
181	Tau protein is phosphorylated by cyclic AMP-dependent protein kinase and calcium/calmodulin-dependent protein kinase II within its microtubule-binding domains at Ser-262 and Ser-356. <i>Biochemical Journal</i> , 1996, 316, 655-660.	1.7	136
182	The Microtubule-associated Protein Tau Is Extensively Modified with O-linked N-acetylglucosamine. <i>Journal of Biological Chemistry</i> , 1996, 271, 28741-28744.	1.6	296
183	Detection of Phosphorylated Ser262 in Fetal Tau, Adult Tau, and Paired Helical Filament Tau. <i>Journal of Biological Chemistry</i> , 1995, 270, 18917-18922.	1.6	319
184	Metal-catalyzed oxidation of bovine neurofilaments in vitro. <i>Free Radical Biology and Medicine</i> , 1995, 18, 891-899.	1.3	33
185	Postnatal changes in serine/threonine protein phosphatases and their association with the microtubules. <i>Developmental Brain Research</i> , 1995, 90, 54-61.	2.1	21
186	Localization and in Situ Phosphorylation State of Nuclear Tau. <i>Experimental Cell Research</i> , 1995, 220, 332-337.	1.2	87
187	Understanding the hyperphosphorylation of tau in Alzheimer's disease: Importance of examining site-specific phosphorylation in non-disease systems. <i>Neurobiology of Aging</i> , 1995, 16, 371-374.	1.5	31
188	τ ₁ Self-Association: Stabilization with a Chemical Cross-Linker and Modulation by Phosphorylation and Oxidation State. <i>Journal of Neurochemistry</i> , 1995, 64, 1209-1215.	2.1	33
189	Phosphorylation of τ ₁ In Situ: Inhibition of Calcium-Dependent Proteolysis. <i>Journal of Neurochemistry</i> , 1995, 65, 903-911.	2.1	52
190	Transglutaminase Cross-Linking of the τ ₁ Protein. <i>Journal of Neurochemistry</i> , 1995, 65, 1760-1770.	2.1	93
191	Compromised mitochondrial function results in dephosphorylation of tau through a calcium-dependent process in rat brain cerebral cortical slices. <i>Neurochemical Research</i> , 1994, 19, 1151-1158.	1.6	24
192	Monoclonal antibody Alz-50 reacts with bovine and human serum albumin. <i>Journal of Neuroscience Research</i> , 1994, 39, 589-594.	1.3	2
193	Transglutaminase facilitates the formation of polymers of the Aβ ₁₋₄₂ -amyloid peptide. <i>Brain Research</i> , 1994, 651, 129-133.	1.1	109
194	Pavlovian conditioning alters cortical microtubule-associated protein-2. <i>NeuroReport</i> , 1994, 5, 1045-1048.	0.6	32
195	Calpain-mediated proteolysis of microtubule-associated protein 2 (MAP-2) is inhibited by phosphorylation by cAMP-dependent protein kinase, but not by Ca ²⁺ /calmodulin-dependent protein kinase II. <i>Journal of Neuroscience Research</i> , 1993, 34, 642-647.	1.3	56
196	Phosphorylation Modulates Calpain-Mediated Proteolysis and Calmodulin Binding of the 200-kDa and 160-kDa Neurofilament Proteins. <i>Journal of Neurochemistry</i> , 1993, 61, 191-199.	2.1	86
197	Transglutaminase Catalyzes the Formation of Sodium Dodecyl Sulfate-Insoluble, Alz-50-Reactive Polymers of τ. <i>Journal of Neurochemistry</i> , 1993, 61, 1159-1162.	2.1	107
198	Metal (Fe ³⁺) affinity chromatography: differential adsorption of tau phosphoproteins. <i>Journal of Neuroscience Methods</i> , 1993, 46, 245-249.	1.3	2

#	ARTICLE	IF	CITATIONS
199	Phosphorylation, calpain proteolysis and tubulin binding of recombinant human tau isoforms. Brain Research, 1993, 604, 32-40.	1.1	58
200	In vitro polymerization of oxidized tau into filaments. Brain Research, 1993, 613, 313-316.	1.1	89
201	Brain casein kinase 2: Affinity purification procedure using immobilized polyethylenimine. Protein Expression and Purification, 1992, 3, 355-361.	0.6	1
202	Alterations of choline acetyltransferase, phosphoinositide hydrolysis, and cytoskeletal proteins in rat brain in response to colchicine administration. Experimental Brain Research, 1992, 89, 496-500.	0.7	6
203	The role of microtubule-associated protein 2 (MAP-2) in neuronal growth, plasticity, and degeneration. Journal of Neuroscience Research, 1992, 33, 505-512.	1.3	304
204	Differential Phosphorylation of τ , by Cyclic AMP-Dependent Protein Kinase and Ca^{2+} /Calmodulin-Dependent Protein Kinase II: Metabolic and Functional Consequences. Journal of Neurochemistry, 1992, 59, 2056-2062.	2.1	48
205	Neurotoxic Effects of Dietary Aluminium. Novartis Foundation Symposium, 1992, 169, 254-267.	1.2	7
206	Seizure-Induced Protein Tyrosine Phosphorylation in Rat Brain Regions. Epilepsia, 1991, 32, 755-760.	2.6	19
207	Degradation of Microtubule-Associated Protein 2 and Brain Spectrin by Calpain: A Comparative Study. Journal of Neurochemistry, 1991, 56, 1630-1638.	2.1	180
208	Proteolysis of Microtubule-Associated Protein 2 and Tubulin by Cathepsin D. Journal of Neurochemistry, 1991, 57, 1577-1583.	2.1	32
209	The regulatory role of calmodulin in the proteolysis of individual neurofilament proteins by calpain. Neurochemical Research, 1991, 16, 869-873.	1.6	55
210	Oral aluminum alters in vitro protein phosphorylation and kinase activities in rat brain. Neurobiology of Aging, 1990, 11, 209-216.	1.5	49
211	Aluminum Increases Agonist-Stimulated Cyclic AMP Production in Rat Cerebral Cortical Slices. Journal of Neurochemistry, 1989, 53, 258-263.	2.1	18
212	Proteolysis of tau by calpain. Biochemical and Biophysical Research Communications, 1989, 163, 1505-1511.	1.0	174
213	Dose- and time-dependent hippocampal cholinergic lesions induced by ethylcholine mustard aziridinium ion: Effects of nerve growth factor, GM1 ganglioside, and vitamin E. Neurochemical Research, 1988, 13, 685-692.	1.6	25
214	The effects of aluminum on agonist-induced alterations in cyclic AMP and cyclic GMP concentrations in rat brain regions in vivo. Toxicology, 1988, 51, 299-308.	2.0	9
215	Phosphorylation of rat brain cytoskeletal proteins is increased after orally administered aluminum. Brain Research, 1988, 456, 95-103.	1.1	59
216	Aluminum alters cyclic AMP and cyclic GMP levels but not presynaptic cholinergic markers in rat brain in vivo. Brain Research, 1987, 403, 1-6.	1.1	61

#	ARTICLE	IF	CITATIONS
217	In vitro measurements of cholinergic activity in brain regions of hibernating ground squirrels. Brain Research Bulletin, 1987, 18, 663-667.	1.4	6
218	Modulation of carbachol-stimulated inositol phospholipid hydrolysis in rat cerebral cortex. Neurochemical Research, 1987, 12, 693-700.	1.6	45
219	Aluminum increases cyclic AMP in rat cerebral cortex. Life Sciences, 1986, 39, 1301-1305.	2.0	10
220	Aluminum impairs glucose utilization and cholinergic activity in rat brain in vitro. Toxicology, 1986, 40, 93-102.	2.0	67
221	Choline Uptake, Acetylcholine Synthesis and Release, and Halothane Effects in Synaptosomes. Anesthesia and Analgesia, 1985, 64, 395-399.	1.1	13
222	Halothane-Induced Alterations of Glucose and Pyruvate Metabolism in Rat Cerebra Synaptosomes. Journal of Neurochemistry, 1985, 44, 1838-1844.	2.1	2